https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Immunotherapy 2012 Jul;4(7):703-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Immunotherapy 2012 Jul;4(7):703-182012-07-01 00:00:002019-02-15 08:39:54Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1834-412012-07-01 00:00:002019-02-15 09:21:39Recent clinical experience with oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Curr Pharm Biotechnol 2012 Jul;13(9):1817-332012-07-01 00:00:002019-02-15 09:23:09Bugs and drugs: oncolytic virotherapy in combination with chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-28 / Lancet Oncol. 2012 Jul;13(7):e301-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-28 / Lancet Oncol. 2012 Jul;13(7):e301-102012-06-28 00:00:002012-06-28 00:00:00Immunotherapies for non-small-cell lung cancer and mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-12 / Int J Hyperthermia 2012;28(6):554-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-12 / Int J Hyperthermia 2012;28(6):554-612012-06-12 00:00:002019-02-15 08:35:41Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-12 / Int J Hyperthermia 2012;28(6):528-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-12 / Int J Hyperthermia 2012;28(6):528-422012-06-12 00:00:002019-02-15 09:17:16Old and new facts about hyperthermia-induced modulations of the immune system
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2546)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2546)2012-06-04 12:06:592019-07-17 12:07:32Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)2012-06-04 11:46:052019-07-17 11:46:27Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2506)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2506)2012-06-04 00:00:002021-08-09 07:43:36WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)2012-06-02 12:04:272019-07-17 12:04:49The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
